To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission

Chronic Myeloid Leukemia Clinical Trial

Official title: Stopping Imatinib Therapy in CML Patients With Sustained Molecular Remission

Status Active, not recruiting

Clinical Trial Summary

Patients with chronic myeloid leukemia (CML) are conventionally put on life long therapy with tyrosine kinase inhibitor drugs (Imatinib mesylate in India). Patients who achieve a deep molecular response which has been sustained for at least three years, can be taken off the drug therapy. Thereafter a close monitoring is required to monitor their disease relapse. In case there is evidence of disease recurrence on highly sensitive molecular assays, their drug therapy is restarted. The study aims to identify proportion of patients who can be kept off drug therapy in a state of sustained molecular remission.

Clinical Trial Description

While a large number of studies which have stopped TKI therapy in similar patients exist in Europe and USA, no such study has been done on Indian or other south Asian population. Almost all studies done previously have noted that in relapsed patients, who show disease recurrence on stopping their TKI therapy, their remission state is regained once the TKI therapy is restarted. ;

Related Conditions & MeSH terms

• Chronic Myeloid Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Treatment Free Remission

• NCT number: NCT03062436
• Study type: Interventional
• Source: Command Hospital, India
• Status: Active, not recruiting
• Phase: N/A
• Start date: August 1, 2017
• Completion date: December 2020